selitrectinib
E1555610
UNEXPLORED
Selitrectinib is an investigational next-generation TRK inhibitor designed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| selitrectinib canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T22796801 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: selitrectinib Context triple: [LOXO-195, hasAlternativeName, selitrectinib]
-
A.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
-
B.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
C.
tirabrutinib
Tirabrutinib is a selective small-molecule Bruton’s tyrosine kinase (BTK) inhibitor developed as a targeted therapy for certain B-cell malignancies and autoimmune diseases.
-
D.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
E.
spebrutinib
Spebrutinib is an experimental small-molecule Bruton’s tyrosine kinase (BTK) inhibitor being investigated primarily for the treatment of B-cell malignancies and autoimmune diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: selitrectinib Target entity description: Selitrectinib is an investigational next-generation TRK inhibitor designed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
A.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
-
B.
larotrectinib
Larotrectinib is a targeted cancer therapy that selectively inhibits TRK fusion proteins and is used to treat solid tumors harboring NTRK gene fusions regardless of tumor site.
-
C.
tirabrutinib
Tirabrutinib is a selective small-molecule Bruton’s tyrosine kinase (BTK) inhibitor developed as a targeted therapy for certain B-cell malignancies and autoimmune diseases.
-
D.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
E.
spebrutinib
Spebrutinib is an experimental small-molecule Bruton’s tyrosine kinase (BTK) inhibitor being investigated primarily for the treatment of B-cell malignancies and autoimmune diseases.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.